SOUTH PLAINFIELD, N.J., Feb. 3, 2020 /PRNewswire/ --PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced real-world data showing that boys with nonsense mutation Duchenne muscular dystrophy treated with Translarna (ataluren) and standard of care (SoC), preserved the ability to walk for years longer than those on SoC alone. Continue reading →

DUBLIN--(BUSINESS WIRE)--Feb 5, 2020-- The "Gene Therapy Market by Vectors [Non-viral (Oligonucleotides), Viral (Retroviral (Gammaretroviral, Lentiviral)), Adeno-associated], Indication (Cancer, Neurological Diseases), Delivery Method (In Vivo, Ex Vivo), Region - Global Forecast to 2024" report has been added to ResearchAndMarkets.com's offering. High incidence of cancer & other target diseases is a major factor driving the growth of the gene therapy market The high incidence of cancer and other target diseases, availability of reimbursement, and the launch of new products are the major factors driving the growth of this market. Continue reading →

Catabasis Pharmaceuticals, Inc. Continue reading →

DUBLIN, Jan. 30, 2020 /PRNewswire/ -- The "Gene Therapy Market by Vectors [Non-viral (Oligonucleotides), Viral (Retroviral (Gammaretroviral, Lentiviral)), Adeno-associated], Indication (Cancer, Neurological Diseases), Delivery Method (In Vivo, Ex Vivo), Region - Global Forecast to 2024" report has been added to ResearchAndMarkets.com's offering Continue reading →

Last year, the death of an immuno-compromised elderly patient in a fecal microbiota transplantation trial due to a donation that contained a rare type of E. coli bacteria sent shivers across the field. The incident marred an otherwise exploding field of drug development that backed replenishing the gut with good bacteria as a safe and effective means to fortify the immune system to fight disease. Continue reading →